Patent · US Active

Reconstituted HDL formulation

US9125943B2 · kind B2 · utility

14Cited by

2References

25Claims

0Family size

Assignee

CSL LIMITED · AU

Inventors

Yvonne Vucica · Bern, CH
Gary Lee Warren · Bourbonnais, US

Key dates

Filing date	Mar 14, 2013
Grant date	Sep 8, 2015
Priority date	—
Expiry date	Mar 14, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/775
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.